Patients with MI after PSM Patients with MI after PSM Patients with MI after PSM
Variables Yes (n=6) No (n=170) p value (OR)
Age, years, median (IQR) 77.5 (33) 69 (26) 0.1
Gender, male, n (%) 5 (83.3) 76 (44.7) 0.06
Duration of hospitalisation (days), median (IQR) 9 (14.5) 10 (9.3) 0.9
Comorbidities, n (%)
Diabetes mellitus 2 (33.3) 54 (31.8) 0.9
Hypertension 3 (50) 99/168 (59) 0.7
Coronary heart disease 4 (66.7) 34/168 (20.2) 0.007 (7.3)
Chronic renal failure 1 (16.7) 23 (13.5) 0.8
Chronic obstructive lung disease 2 (33.3) 26/168 (15.5) 0.2
Malignancy 2 (33.3) 12 (7) 0.02 (5.5)
Vaccination history 1/4 (25) 48/102 (47) 0.4
Disease severity, n (%)
NIH score 3 (severe) 0 82 (48.2) 0.02 (5.4)
NIH score 4 (critical) 6 (100) 88 (51.8)
Vaccination history, median (IQR) 2 (1) 0.5
mcHIS score, median (IQR) 4.5 (1.25) 3 (2) 0.02
Laboratory results
Neutrophil to lymphocyte ratio, median (IQR) 4 (6) 5.9 (6.8) 0.6
Hemoglobin (g/L), mean±SD 12.8±1.3 13.3±2.2 0.5
Creatinine (mg/dL), median (IQR) 1 (0.66) 0.87 (0.54) 0.5
Prokalsitonin (pg/dL), median (IQR) NA 0.18 (0.44) NA
C-reactive protein (mg/L), median (IQR)
1 129 (164) 107 (117) 0.6
2 144.8 (74) 138.6 (110) 0.043
3 207.6 (80) 11.5 (80) 0.003
Ferritin (pg/mL), median (IQR)
1 NA 331 (545) NA
2 1001 (761) 542 (848) 0.096
3 1001 (687) 333 (483) 0.009
D-dimer (pg/mL), median (IQR)
1 NA 1.2 (1.1) NA
2 27.3 (32.1) 2.7 (8.6) 0.03
3 27.3 (33) 1.2 (2.8) 0.005
Lactate dehydrogenase (U/L), median (IQR)
1 390 (97) 399 (206) 0.8
2 998 (759) 488 (278) 0.004
3 582.5 (684) 355 (172) 0.016
Outcomes, n (%)
Severe infection 3 (50) 35/164 (21.3) 0.1
Pneumothorax 0 2/168 (1.2) 0.8
Treatment
Anakinra 0 88 (100) 0.013 (6.2)
SoC 6 (6.8) 82 (93.2)
ICU requirement 4 (66.7) 53 (31.2) 0.07
Mortality 6 (100) 49 (28.8) <0.001 (13.7)